文献速递流行病学与生物统计医学教育与科研方法

临床试验方案中决策能力相关排除常见,评估有限且几乎无能力丧失预案

Capacity-related exclusions in clinical trial protocols are common, with limited assessment and almost no planning for capacity loss.
PubMed 文献 · J Clin Epidemiol · 2026-09-23

该研究对500份临床试验方案进行结构化内容分析,发现61%(306份)含决策能力相关标准,但仅17%(53/306)描述评估方法,仅1%(3份)包含参与者能力丧失预案。方案阶段对决策能力评估与能力丧失规划文档化不足,引发透明性与包容性担忧。

要点

  • 61%试验方案含决策能力相关入选或排除标准,其中43%直接以决策能力决定入选。
  • 仅17%含能力相关标准的方案描述评估方法,评估者多为非临床人员。
  • 仅1%方案包含参与者试验期间能力丧失的应对预案。

核心结论

  • 临床试验方案中决策能力相关排除常见,但评估过程与能力丧失规划文档化严重不足。

研究设计与样本

  • 对从824份方案数据集中按倒序筛选至500份临床试验方案进行结构化内容分析。
  • 提取能力相关入选排除标准、评估执行者、评估者培训及能力丧失处理流程,采用描述性统计汇总。

主要发现

  • 500份方案中214份(43%)直接基于决策能力做出入选决定,另92份(18%)通过知情同意要求间接涉及能力,合计306份(61%)含能力相关标准。
  • 306份含能力相关标准的方案中仅53份(17%)描述能力评估方式,其中28份明确评估执行者,仅2份提及评估者培训。
  • 评估者多为非临床人员,仅3份方案(1%)包含参与者研究期间能力丧失的预案。

临床怎么用

  • 方案设计时应明确决策能力评估方法、评估执行者资质与培训要求,并制定能力丧失应对预案。
  • 加强方案阶段透明性与指导,有助于避免有损或波动性决策能力者被不合伦理或系统性排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: People who are assumed to have impaired decision-making capacity continue to be under-served in clinical research, despite legislation aimed at supporting their inclusion. Previous studies have highlighted the routine exclusion of individuals with intellectual disabilities or cognitive impairments, but little is known about how capacity-related decisions are documented at the protocol stage. This study examines how clinical trial protocols describe the inclusion or exclusion of individuals with impaired capacity, the assessment of capacity, and any plans for participants who might lose capacity during a trial. METHODS: A structured content analysis was conducted on 500 clinical trial protocols selected from a larger dataset of 824 protocols previously identified for another study. Protocols were screened in reverse chronological order until the target number was reached. Extraction focused on capacity-related eligibility criteria, who conducted capacity assessments, any mention of training of assessors, and procedures for participants who might lose capacity. Descriptive statistics were used to summarise findings. RESULTS: Of the 500 trial protocols reviewed, 214 (43%) made direct eligibility decisions based on decision-making capacity, and a further 92 (18%) referenced capacity indirectly through informed consent requirements, totalling 306 protocols (61%) with capacity-related criteria. Only 53 protocols (53/306, 17%) described how capacity would be assessed, 28 of these 53 identified who would conduct the assessment, and just two mentioned any assessor training. Most assessors were non-clinical staff. Just three protocols (1%) included plans for participants who might lose capacity during the study. CONCLUSION: This study demonstrates that capacity-related exclusions are common in clinical trial protocols, yet the processes behind these decisions are poorly documented. The lack of detail regarding assessors, training, and loss-of-capacity planning raises concerns about transparency and inclusion. Strengthening transparency and guidance at the protocol stage could help ensure that individuals with impaired or fluctuating capacity are not unethically or systematically excluded from research.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. McGovern M, Russell AM, Shiely F, et al. Capacity-related exclusions in clinical trial protocols are common, with limited assessment and almost no planning for capacity loss. J Clin Epidemiol. 2026. PMID: 42777843. doi:10.1016/j.jclinepi.2026.112534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。